RubenReyesMD

Hematology • Westwood, KS

Assistant Professor, Internal Medicine, University Kansas School of Medicine

Join to view full profile

Dr. Reyes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reyes' full profile

Already have an account?

Office
2330 Shawnee Mission Pkwy
Suite 210
Westwood, KS 66205
Phone+1 913-588-6029

Fax+1 252-744-3418

Education & Training

Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Superior Institute of Medical Sciences of Santiago de CubaClass of 1986

Certifications & Licensure

KS State Medical License 2009 - 2015

Clinical Trials

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine Start of enrollment: 2010 Jan 01
Completed
Early Phase 1
A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 1
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3

Publications & Presentations

PubMed

281 citations
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale
Journal of Clinical Oncology. 2016-09-19
55 citations
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute mye...
Casey Williams, Suman Kambhampati, Warren Fiskus, Jo Wick, Catherine Dutreix
Pharmacotherapy. 2013-12-01
43 citations
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Sarit Assouline, Julie E. Chang, Bruce D. Cheson, Robert M. Rifkin, Solomon I. Hamburg
Blood Cancer Journal. 2014-10-17